Home  /  Resource Library  /  Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

Results of a phase II study investigating camrelizumab combined with decitabine for treatment of relapsed Hodgkin lymphoma.